Successful hybrid stage I palliation for hypoplastic left heart syndrome in a developing nation

Charles C Cuaso1, Dexter D Cheng, Jonas Del Rosario

  • 1Section of Pediatric Cardiology, Congenital Heart Disease Division of the Heart Institute, St. Luke's Medical Center, Quezon City Philippines.

Insights

This report details the first successful Stage I palliation surgery for hypoplastic left heart syndrome (HLHS) in the Philippines. The study highlights unique challenges and offers cautious optimism for pediatric cardiac surgery in developing nations.

Area of Science:

  • Pediatric Cardiac Surgery
  • Congenital Heart Defects
  • Global Health

Background:

  • Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect requiring complex surgical palliation.
  • Performing advanced pediatric cardiac surgery in developing nations presents unique logistical and resource challenges.
  • Successful surgical outcomes are crucial for improving survival rates in infants with HLHS.

Purpose of the Study:

  • To report the first successful Stage I palliation for HLHS in a pediatric patient in the Philippines.
  • To discuss the specific challenges encountered during the preoperative, perioperative, and interstage periods in a developing country context.
  • To provide insights into the feasibility and potential for advancing pediatric cardiac surgery in resource-limited settings.

Main Methods:

  • Case report of a four-day-old female infant undergoing Stage I palliation for HLHS.
  • Detailed description of surgical procedures and anesthetic management.
  • Analysis of challenges faced, including resource availability, team training, and post-operative care.

Main Results:

  • Successful completion of Stage I palliation for HLHS in the reported case.
  • Identification of significant challenges related to infrastructure, equipment, and specialized personnel.
  • Demonstration of successful interstage management despite resource limitations.

Conclusions:

  • The successful palliation of HLHS in the Philippines demonstrates the potential for advanced pediatric cardiac surgery in developing nations.
  • Addressing specific challenges is critical for improving outcomes and expanding access to care.
  • This experience offers cautious optimism for future surgical interventions and capacity building in similar settings.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...